Non-Small-Cell Lung Carcinoma Clinical Trial
Official title:
Phase I Trial of Motexafin Gadolinium (MGd) in Combination With Docetaxel and Cisplatin for Treatment of Non-Small Cell Lung Cancer (NSCLC)
| NCT number | NCT00102505 |
| Other study ID # | PCYC-0220 |
| Secondary ID | |
| Status | Completed |
| Phase | Phase 1 |
| First received | January 29, 2005 |
| Last updated | April 2, 2009 |
| Start date | November 2004 |
| Verified date | April 2009 |
| Source | Pharmacyclics |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | United States: Food and Drug Administration |
| Study type | Interventional |
The purpose of the study is to determine the dose limiting toxicities and maximum tolerated
dose of motexafin gadolinium when administered with docetaxel and cisplatin in patients with
Non-small Cell Lung Cancer.
A cycle consists of 3 weeks. During week 1, patients receive MGd, docetaxel, and cisplatin
treatment followed by 2 weeks without treatment.
Eligible patients will receive 1 or 2 doses of MGd, depending on cohort, and a single dose
of docetaxel and cisplatin at 75 mg/m² during the first week of each cycle. Additionally,
tumor response will be evaluated at the end of even numbered cycles (2, 4, and 6). Patients
may stay on the study a maximum of 6 cycles.
| Status | Completed |
| Enrollment | 36 |
| Est. completion date | |
| Est. primary completion date | |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - = 18 years old - ECOG score of 0, 1, or 2 - Histologically confirmed diagnosis of non-small cell lung cancer Exclusion Criteria: Laboratory values demonstrating inadequate function of the following: - Bone marrow - Kidneys - Liver and - Peripheral neuropathy Grade 2 or higher - Greater than 2 prior chemotherapy regimens |
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| United States | The University of Texas MD Anderson Cancer Center | Houston | Texas |
| Lead Sponsor | Collaborator |
|---|---|
| Pharmacyclics |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Dose limiting toxicities of MGd when administered concurrently with docetaxel and cisplatin | |||
| Primary | Maximum tolerated dose of MGd when administered concurrently with docetaxel and cisplatin | |||
| Secondary | Tumor response |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00985855 -
Feasibility of Cetuximab Associated With Concomitant Radio-Chemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT01048645 -
Effect of All-trans Retinoic Acid With Chemotherapy Based in Paclitaxel and Cisplatin as First Line Treatment of Patients With Advanced Non-small Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT00129844 -
Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT00098085 -
Study of the Feasibility to Derive Vaccine From Tumor Tissue in Patients With Non-Small Cell Lung Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT04995523 -
A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC
|
Phase 1/Phase 2 | |
| Completed |
NCT00910676 -
Study About Preventive Treatment of Folliculitis Induced by Epidermal Growth Factor Receptor Inhibitors
|
Phase 2 | |
| Withdrawn |
NCT00108186 -
Celecoxib Treatment for Lung Cancer
|
Phase 1 | |
| Recruiting |
NCT05037825 -
The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors
|
||
| Recruiting |
NCT00379717 -
Concurrent Helical Tomotherapy With Chemotherapy in Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1/Phase 2 | |
| Completed |
NCT00404924 -
ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures
|
Phase 3 | |
| Recruiting |
NCT02905591 -
A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC
|
Phase 2 | |
| Active, not recruiting |
NCT03088540 -
Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)
|
Phase 3 | |
| Terminated |
NCT00271323 -
Safety Study of Docetaxel/Cisplatin Induction Therapy Followed by Concurrent Chemoradiotherapy or Concurrent Chemoradiotherapy Followed by Consolidation Docetaxel/Cisplatin in NSCLC Patients
|
Phase 2 | |
| Terminated |
NCT00232206 -
Trial of Neoadjuvant Docetaxel and Cisplatin for Resectable Non-Small Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT00037817 -
Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural Malignancies
|
Phase 1 | |
| Completed |
NCT03444766 -
Study of Nivolumab for Advanced Cancers in India
|
Phase 4 | |
| Completed |
NCT04351334 -
Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC) Post-alectinib Treatment Patterns
|
||
| Active, not recruiting |
NCT02416739 -
Anticancer Activity of Nicotinamide on Lung Cancer
|
Phase 2/Phase 3 | |
| Completed |
NCT00444015 -
Phase I Dasatinib/Erlotinib in Recurrent Non-small Cell Lung Cancer (NSCLC)
|
Phase 1 | |
| Completed |
NCT00105092 -
Enzastaurin as Second and Third-Line Treatment for Non-Small Cell Lung Cancer.
|
Phase 2 |